Compass Therapeutics, Inc. filed a Form 8-K on November 20, 2026, disclosing that it received a Nasdaq deficiency letter on November 19, 2026, notifying the company that its common stock has failed to meet the minimum $1.00 per share closing bid price requirement for continued listing on The Nasdaq Capital Market.
Key Highlights
- Deficiency letter received: Compass Therapeutics received written notice from the Nasdaq Listing Qualifications Department on November 19, 2026, citing a failure to meet the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2).
- 30 consecutive business days below $1.00: According to the filing, the closing bid price of the company's common stock had been below $1.00 per share for the last 30 consecutive business days.
- 180-day compliance window: The company has been given 180 calendar days, or until May 18, 2027, to regain compliance with the Minimum Bid Price Requirement.
- No immediate listing impact: The filing states that "the Nasdaq deficiency letter has no immediate effect on the listing of the Company's common stock," which will continue to trade on NASDAQ:CMPX.
- Reverse stock split considered: The company disclosed it may consider available options to regain compliance, "including effecting a reverse stock split."
- Potential second compliance period: If compliance is not achieved by May 18, 2027, the company may qualify for a second 180-calendar-day period, subject to meeting other Nasdaq listing standards.
Compass Therapeutics Discloses Nasdaq Minimum Bid Price Deficiency and Compliance Timeline
According to the Form 8-K filed with the SEC on November 20, 2026, Compass Therapeutics, Inc. received a deficiency letter from Nasdaq's Listing Qualifications Department on November 19, 2026. The letter notified the company that its common stock had closed below the $1.00 per share minimum bid price required under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days. The filing states the deficiency letter "has no immediate effect on the listing of the Company's common stock," which continues to trade on The Nasdaq Capital Market under the symbol CMPX.
Under Nasdaq Listing Rule 5810(c)(3)(A), the company has until May 18, 2027 - a period of 180 calendar days - to restore compliance. The filing states that if, at any time before that deadline, the bid price closes at $1.00 per share or more for at least 10 consecutive business days, Nasdaq staff will provide written confirmation of compliance. The company disclosed it intends to monitor its closing bid price and "may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement, including effecting a reverse stock split."
If the company does not regain compliance by May 18, 2027, it may be eligible for a second 180-calendar-day compliance period. To qualify for that second period, the filing states, the company would need to meet continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except the Minimum Bid Price Requirement, and would also need to notify Nasdaq of its intent to cure the deficiency, potentially via a reverse stock split. The filing also notes that if a delisting notice is ultimately received, Nasdaq rules permit an appeal to a Nasdaq Hearings Panel, though the filing cautions there is "no assurance" such an appeal would succeed. The 8-K was signed by Neil Lerner, Chief Accounting Officer, on November 20, 2026.
What Was Disclosed
Compass Therapeutics disclosed receipt of a Nasdaq bid price deficiency notice dated November 19, 2026, citing 30 consecutive business days below $1.00 per share, with a compliance deadline of May 18, 2027, and no immediate effect on its current listing status.




Please wait processing your request...